– NDA submission for etripamil in patients with PSVT currently on track for 3Q23 – Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on Monday, May 22, 2023 – Topline data from Phase 2 ReVeRA study evaluating etripamil in patients with AFib-RVR expected in 2H, 2023 – […]
Other News
Investor Insights: Gwen Watanabe – At What Stage Does H.I.G. Capital Typically Invest?
McDermott + Bull Partner Ken Dropiewski talks with H.I.G. Capital Managing Director Gwen Watanabe about when they typically invest.
Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update
PONTE VEDRA, Fla., May 10, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with today’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, […]
Akura Medical Announces Successful First-in-Human Use of its High Performance Mechanical Thrombectomy Platform
Initial cases, proctored by 2 leading US interventionalists, mark the first use of mechanical thrombectomy for pulmonary embolism in the Republic of Georgia Akura’s platform, which will be featured at PCR Innovator’s Day, uses a differentiated approach to deliver high performance for patients with VTE LOS GATOS, Calif., May 10, 2023 /PRNewswire/ — Akura […]
Silk Road Medical Reports First Quarter 2023 Financial Results
SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2023. “2023 is off to a strong start as we execute against […]
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
PRESS RELEASE REGULATED INFORMATION 10 May 2023, 06:00 p.m. CEST Ghent, Belgium, 10 May 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that following the private placement of new shares and new subscription rights that was announced on […]
Quanterix Releases Operating Results for First Quarter 2023
BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended March 31, 2023. “Our corporate transformation initiated in August 2022 to maximize Quanterix’s full potential is on track. We remain confident that we have taken the right […]
Transforming Heart Disease Prevention for Self-Insured Employers in Oklahoma, Missouri, Kansas, and Arkansas: A Strategic Alliance between Connect Clinic and Cardio Diagnostics
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced a partnership with Connect Clinic to help MidWest/South Central self-insured employers build access to heart disease initiatives. These states lack ready access to precision heart disease technologies needed to tackle cardiovascular disease at scale while also having […]
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
– Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study – – Registrational Phase 3 Clinical Trial in PAH Patients Expected to Initiate in 3Q23 – – Initial TORREY Study Open-Label Extension Data Expected Mid 2023 – – Operational Restructuring Implemented […]
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced that it intends to deliver an irrevocable notice of redemption, on or about May 15, 2023, to redeem all of the common […]
Recent
Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
First Peer-Reviewed Study to Evaluate AI-Generated Impressions Demonstrates Radiologist Preference for Domain-Specific Versus General Models
Popular
- No commented posts yet